Analyst Price Target Update on Incyte Corporation (NASDAQ:INCY)

Incyte Corporation (NASDAQ:INCY): According to 10 Analysts, The short term target price has been estimated at $ 93.6.The target price could deviate by a maximum of $16.68 from the forecast price. In the near term, the target price could hit a high of $135 and a low of $ 76.

Many analysts have stated their opinion on the company shares. BMO Capital initiates coverage on Incyte Corporation (NASDAQ:INCY) The brokerage firm has issued a Outperform rating on the shares. The rating by the firm was issued on April 7, 2016. For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities,The officer (EVP, Human Resources) of Incyte Corp, Swain Paula J sold 13,531 shares at $76.96 on January 15, 2016. The Insider selling transaction had a total value worth of $1,041,346. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Incyte Corporation (NASDAQ:INCY) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.4 points or 0.5% at $80.01 with 959,266 shares getting traded. Post opening the session at $80.08, the shares hit an intraday low of $79.48 and an intraday high of $82.47 and the price was in this range throughout the day. The company has a market cap of $15,011 million and the number of outstanding shares have been calculated to be 187,619,380 shares. The 52-week high of Incyte Corporation (NASDAQ:INCY) is $133.62 and the 52-week low is $55.

Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *